# Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Source: https://onco.cc/trials/nct07405164/  
OnCo record `nct07405164` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Belzutifan, Nivolumab, Lenvatinib and Cabozantinib in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) is a phase 3 interventional study registered as NCT07405164 by Merck Sharp & Dohme LLC, with 450 participants planned, started 2026-03-23 and due to reach its primary completion in 2034-01-14. Interventions recorded: Belzutifan, Nivolumab, Lenvatinib and Cabozantinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07405164
- Phase: 3
- Setting: A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT07405164: https://clinicaltrials.gov/study/NCT07405164

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Belzutifan](https://onco.cc/drugs/belzutifan/), [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07405164.json